Celecoxib for the prevention of colorectal adenomatous polyps

New England Journal of Medicine

Volumn 355, Issue 9, 2006, Pages 885-895

  Arber, Nadir ^a   Eagle, Craig J ^b   Spicak, Julius ^c   Rácz, István ^g   Dite, Petr ^d   Hajer, Jan ^e   Zavoral, Miroslav ^f   Lechuga, Maria J ^b   Gerletti, Paola ^b   Tang, Jie ^b   Rosenstein, Rebecca B ^b   Macdonald, Katie ^b   Bhadra, Pritha ^b   Fowler, Robert ^h   Wittes, Janet ^h   Zauber, Ann G ⁱ   Solomon, Scott D ^j   Levin, Bernard ^k  

^a TEL AVIV UNIVERSITY   (Israel)

^b PFIZER INC   (United States)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f CENTRAL MILITARY HOSPITAL   (Czech Republic)

^g Endocrinology and Diabetology   (Hungary)

^h University of Iowa   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; PLACEBO; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE; ADENOMA; ADENOMATOUS POLYP; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG COMBINATION; GASTROINTESTINAL DISEASE; KIDNEY DISEASE; MIDDLE AGED; MORTALITY; RECURRENT DISEASE;

ADENOMA; ADENOMATOUS POLYPS; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PYRAZOLES; RECURRENCE; SULFONAMIDES;

EID: 33748180713     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa061652     Document Type: Article

References (22)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
2. Ferlay J, Bray P, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Lyon, France: IARC Press, 2004.
3. Cancer facts and figures, 2006. Atlanta: American Cancer Society, 2006.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
5. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in subjects with previous colorectal cancer. N Engl J Med 2003;348:883-90. [Erratum, N Engl J Med 2003;348:1939.]
6. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
7. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9.
8. Tanaka Y, Ward SL, Smith WL. Immunochemical and kinetic evidence for two different prostaglandin H-prostaglandin E isomerases in sheep vesicular gland microsomes. J Biol Chem 1987;262:1374-81.
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
10. Sinicrope FA, Lemoine M, Xi L, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999;117:350-8.
11. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
13. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
14. Celebrex (celecoxib). New York: Pfizer, July 2005 (package insert).
15. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80 (supplementary appendix, Web only). (Available at content.nejm.org/cgi/data/NEJMoa050405/DC1/1.)
16. Koch GG, McCanless I, Ward JF Jr. Interpretation of statistical methodology associated with maintenance trials. Am J Med 1984;77:Suppl 5B:43-50.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
18. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. 2nd ed. Cary, N.C.: SAS Institute, 2000.
19. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning, 1982:342-51, 359.
20. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975:132-7, 145.
21. Shureiqi I, Wu Y, Chen D, et al. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 2005;65:11486-92.
22. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.